The Medicines and Healthcare products Regulatory Agency (MHRA) recently launched a toolkit for healthcare professionals (HCPs) regarding sodium valproate in order to communicate its teratogenic effects. The CEU recommends that all HCPs be prepared to provide information about and access to effective contraception for women who have undergone treatment with valproate-related medicines.
This statement aims to encourage the consistent and safe management of women requesting intrauterine contraception (IUC) and subdermal implants (SDI) who are taking anticoagulants or antiplatelet medications. It is primarily aimed at clinicians working in primary care and community sexual and reproductive health clinics.
This statement provides guidance on contraceptive choices for transgender and non-binary people and their partners, who are engaging in vaginal sex where there is a risk of pregnancy. The statement also offers general sexual health advice for these groups.
This statement summarises the available evidence regarding how contraception may affect a woman’s weight and how a woman’s weight may affect contraceptive efficacy. Looking at each method individually, the CEU advises clinicians on what proven and theoretical associations exist between contraception and weight.
The recent article in the Telegraph newspaper has highlighted the complex issues surrounding sexual activity in young women in the UK. Whilst it is true that the legal age of consent to sexual activity in the UK is 16 years, surveys suggest that almost one in three young people will have had sexual intercourse by this age.